Promoter methylation of Wnt-antagonists in polypoid and nonpolypoid colorectal adenomas


Nonpolypoid adenomas are a subgroup of colorectal adenomas that have been associated with a more aggressive clinical behaviour compared to their polypoid counterparts. A substantial proportion of nonpolypoid and polypoid adenomas lack APC mutations, APC methylation or chromosomal loss of the APC locus on chromosome 5q, suggesting the involvement of other Wnt-pathway genes.

The present study investigated promoter methylation of several Wnt-pathway antagonists in both nonpolypoid and polypoid adenomas.

Methods:
Quantitative methylation-specific PCR (qMSP) was used to evaluate methylation of four Wnt-antagonists, SFRP2, WIF-1, DKK3 and SOX17 in 18 normal colorectal mucosa samples, 9 colorectal cancer cell lines, 18 carcinomas, 44 nonpolypoid and 44 polypoid adenomas. Results were integrated with previously obtained data on APC mutation, methylation and chromosome 5q status from the same samples.

Results:
Increased methylation of all genes was found in the majority of cell lines, adenomas and carcinomas compared to normal controls.

WIF-1 and DKK3 showed a significantly lower level of methylation in nonpolypoid compared to polypoid adenomas (p

Conclusions:
Methylation of Wnt-pathway antagonists represents an additional mechanism of constitutive Wnt-pathway activation in colorectal adenomas.

Current results further substantiate the existence of partially alternative Wnt-pathway disruption mechanisms in nonpolypoid compared to polypoid adenomas, in line with previous observations.

Author: Quirinus JM VoorhamJerry JanssenMarianne TijssenSuzanne SnellenbergSandra MongeraNicole CT van GriekenHeike GrabschMartin KlimentBjorn J RembackenChris JJ MulderManon van EngelandGerrit A MeijerRenske DM SteenbergenBeatriz Carvalho
Credits/Sour

Published on: 2013-12-19

Tweet

News Provider: EUPB – European Press Bureau

Social Bookmarking
RETWEET This! | Digg this! | Post to del.icio.us | Post to Furl | Add to Netscape | Add to Yahoo! | Rojo

There are no comments available. Be the first to write a comment.